Business Wire

MODULEX-GRUPPEN

Del
MODULEX GRUPPEN OFFENTLIGGØR NY CFOO

Modulex Gruppen er glade for at kunne annoncere udnævnelsen af Mikkel Arreborg som Chief Finance og Operations Officer med base i koncernens hovedkvarter i Billund. Mikkel har en baggrund som CFO med en dokumenteret track record for strategisk finansielt lederskab og operationel ekspertise på tværs af forskellige brancher.

I løbet af sin tid som CFO hos Auto Solutions Group demonstrerede Mikkel enestående færdigheder i at styre finansielle operationer på tværs af et konglomerat af virksomheder. Hans ansvarsområder omfattede tilsyn med budgettering, finansiel rapportering og aktiv deltagelse i bestyrelsesmøder. Han stod især i spidsen for en omfattende omstrukturering af økonomiafdelingen og implementerede nye systemer og processer for at øge effektiviteten. Mikkel spillede en afgørende rolle i det succesfulde opkøb af Etac Bil i Norge, hvor han viste sin instrumentelle rolle i opkøb og integrationer.

"Det er mig en stor ære at blive en del af Modulex-teamet", siger Mikkel Arreborg. "Jeg er meget begejstret for at deltage i den spændende rejse, der ligger forude for koncernen, og den enestående mulighed for at lære af og bidrage til alle Modulex enheder på tværs af forskellige lande og kulturer."

Før han kom til Modulex Gruppen, havde Mikkel betydelige roller hos bl.a. PwC og BDO. Han har en kandidatgrad i revision og en diplomuddannelse i erhvervsøkonomi med speciale i regnskab og økonomistyring.

Ketil M. Staalesen, CEO i Modulex Gruppen, er begejstret for udnævnelsen af Mikkel og udtaler: "Jeg er virkelig begejstret for, at Mikkel har besluttet sig for at blive en del af vores team. Det er en meget vigtig rolle i fremtiden for den globale koncern, og det er en rolle, jeg arbejder meget tæt sammen med. Jeg var imponeret over Mikkels strategiske sans, hans umiddelbare observation af, hvordan han kunne gøre en forskel, og hans begejstring for at lære og lære alle forretningsenhederne at kende globalt."

Mikkel er en indflydelsesrig leder, der er forpligtet til at fremme et samarbejdsmiljø og bidrage til Modulex' formålsdrevne virksomhedskultur.

For mere information om Modulex, besøg vores hjemmeside https://modulex.com/ eller kontakt vores medierelationsteam på media@modulex.com

Om Modulex Gruppen:

Modulex blev grundlagt i 1963 af LEGO Koncernen og har siden 2009 været ejet af ledende partnere og eksterne investorer og er globalt førende inden for visuel kommunikation. Med rødder i dansk design excellence og et modulært skiltningskoncept har Modulex udviklet sin platform med design, wayfinding, skræddersyede løsninger og brandimplementeringer. I 2019 lancerede Modulex fabrikken i Billund, som er både ISO 9001 og 14001 certificeret, en bæredygtig produktlinje og blev tildelt Green Network-diplomet for 10. gang i træk. Den multinationale koncern har flere produktionsfaciliteter globalt. Koncernen er repræsenteret i over 300 byer i 45 lande.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240522566437/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye